< >

HyperAcute Immunotherapy

NewLink Genetics has multiple HyperAcute immunotherapies currently under development in a variety of tumors

Phase 3 Trial in Pancreatic Cancer

Now enrolling patients with borderline resectable or locally advanced unresectable pancreatic cancer

Phase 2b/3 Trial in Lung Cancer

Now enrolling patients with progressive or relapsed non-small cell lung cancer (NSCLC)

Investor Relations

Keep up with the latest news and presentations
NewLink Genetics to Participate in the Upcoming Stifel, Jeffries, and Piper Jaffray Healthcare Conferences
November 17, 2014

NewLink Genetics Appoints Thomas P. Monath, M.D. to the Position of Chief Scientific and Chief Operations Officer of BioProtection Systems Corporation, Its Infectious Disease Division
November 14, 2014

ANNOUNCEMENTS